

Achaogen
Investor Relations Department
7000 Shoreline Court,
3rd Floor
South San Francisco, CA 94080
United States

[Visit IR website](#) 
[Sign-up for email alerts](#) 

NASDAQ: AKAO

Last Trade:	10.75
Trade Time:	4:00 PM ET Feb 20, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	9.83 - 27.79
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments against multi-drug resistant (MDR), gram-negative infections. We are developing plazomicin, our lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infections (cUTI), bloodstream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). In 2013, the Centers for Disease Control and Prevention identified CRE... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Feb 13, 2018

[Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2017 Financial Results on February 27, 2018](#)

Feb 7, 2018

[Achaogen to Present at the Leerink Partners 7th Annual Global Healthcare Conference](#)

Jan 30, 2018

[Achaogen Announces Upgraded Status for Plazomicin Fill Manufacturer](#)

Jan 25, 2018

[Achaogen Announces New Employment Inducement Grants](#)

Jan 3, 2018

[Achaogen to Present at J.P. Morgan Healthcare Conference](#)

Upcoming Events [\[View all \]](#)

Feb 27, 2018 4:30 PM

[Fourth Quarter and Fiscal Year 2017 Earnings Call](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Mar 14, 2017

[Annual Report \(10-K\)](#)

Apr 26, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 8, 2017

[Quarterly Report \(10-Q\)](#)

Aug 8, 2017

[Quarterly Report \(10-Q\)](#)

May 8, 2017

[Quarterly Report \(10-Q\)](#)